New Compound Safely Halts Advanced Myeloma Progression in Small Pilot Study
A new investigational compound targeting a central…
Myeloma
Myeloma overview
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreMyeloma treatment
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreLatest news
Trip to Mount Everest’s Base Benefits MMRF-funded Multiple Myeloma Research
During a strenuous but spectacular hike, a team including…
Revlimid Delays Disease Progression in Smoldering Myeloma Patients, Preliminary Trial Results Show
Celgene‘s immunomodulatory agent Revlimid (lenalidomide) significantly extended the time…
Darzalex Add-on Increases Complete Responses After Stem Cell Transplant, Phase 3 Myeloma Trial Shows
Adding Darzalex (daratumumab) to the standard pre-transplant therapy…
STRO-001 Receives FDA’s Orphan Drug Status for Multiple Myeloma Treatment
STRO-001, Sutro Biopharma’s investigational therapy for multiple…
Selinexor Granted Priority Review by FDA for Heavily Treated Multiple Myeloma
The U.S. Food and Drug Administration (FDA) has granted…
